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Review Article
Intra‑arterial chemotherapy in retinoblastoma – A paradigm change
Fairooz P Manjandavida1,2, Christina Stathopoulos3, Jing Zhang2, Santhosh G Honavar4, Carol L Shields5
Intra-arterial chemotherapy (IAC), also known as superselective ophthalmic artery chemotherapy or
chemosurgery, is currently widely accepted as one of the primary treatment modalities for intraocular
retinoblastoma worldwide. Following the introduction of the technique in 1998, IAC has evolved over the
past decades to be safer and more effective. Accumulated evidence shows that IAC is more effective in
providing eye salvage in group D and E retinoblastoma as compared to conventional systemic intravenous
chemotherapy (IVC). In contrast to IVC, IAC has the added benefits of reduced overall treatment duration
and minimal systemic toxicity.  This review provides a comprehensive update on the history, technique,
indications, contraindications, and   outcome of IAC. We have also identified the strengths, weaknesses,
opportunities and threats (SWOT analysis) of the technique in this review.
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Retinoblastoma (RB) is one the most successfully treated
pediatric malignancies. Targeted treatment in RB by direct
delivery of chemotherapeutic agents into the ophthalmic
artery (OA) has dramatically changed the approach in the
management of this deadly, yet curable eye cancer.[1‑3] This
technique of intra‑arterial chemotherapy (IAC) through
ophthalmic artery has the advantage of higher concentration
of chemotherapy drugs reaching the tumor, with negligible
systemic side effects when compared with systemic intravenous
chemotherapy (IVC). Over the past decade, we have witnessed
expanding indications of IAC for tumor control and eye
salvage in advanced and refractory retinoblastoma.[4] Prior to
the IAC era, systemic IVC was used as the standard of care.
Systemic IVC has shown encouraging results in salvaging
nearly 100% of group A, B, and C eyes when coupled with
adjunctive laser therapy and cryotherapy. [5‑7] Advanced
group D eyes with diffuse vitreous and subretinal seeds and
group E eyes, however, carried a modest prognosis for eye
salvage with IVC.[8] By achieving higher concentration in the
target tumor, IAC has shown improved outcome in group D
and E retinoblastoma.[9] With these added benefits, IAC has
emerged as the first‑line management option in selected cases,
and its use is expanding. In refractory tumors, IAC has proven
to be effective as a second‑line treatment, leading to improved
salvage of eyes that otherwise would have been enucleated.
However, indications, patient selection, and procedure‑related

complications have raised some concerns. [10‑12] IAC is an
invasive method that requires an experienced multidisciplinary
team including neurosurgeon, interventional neuroradiologist,
pediatric oncologist, and retinoblastoma specialist.[3,13] Used
with caution, and in experienced hands, the benefits of IAC
outweigh the limitations. We now have data over a decade to
be able to assess the long‑term effects of IAC.[12] In this review,
we attempt to summarize the current knowledge about IAC.
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History and Evolution
In 1958, Reese performed IAC through the internal carotid
artery (ICA) as an adjuvant treatment to enhance the
effectiveness of external beam radiotherapy. Triethylene
melamine (TEM), a nitrogen mustard analog, was injected
directly into the ipsilateral internal carotid artery by placing
a suture ligation for traction and hemostasis in 31 patients (61
injections). Due to unfavorable systemic toxicities of TEM,
this procedure was further abandoned and discontinued.[14]
A decade later, in 1968, Kiribuchi from Japan introduced the
retrograde approach of infusion of opthalmic artery by way
of arterial branches of external carotid artery and reported
tumor regression.[15]
We credit the work of Kaneko et al. from Japan for the
reintroduction of IAC that emerged as a valuable alternative
to enucleation in the management of retinoblastoma.[16] Due to
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the cultural barriers arising from the stigma of enucleation in
Japan, there was a need to salvage the eyes with retinoblastoma.
Inomata and Kaneko in 1984 found that melphalan was
superior to other chemotherapeutic drugs in retinoblastoma
in their clonogenic assay, as an effort to improve eye
salvage.[17,18] To reduce the severe myelosuppression with
high‑dose systemic melphalan that is required to achieve target
concentration, they tried an alternate intra‑arterial route for
local delivery of melphalan to attain higher concentration in
the intraocular tumor with negligible systemic toxicity.[16,17]
This led to the pioneering work by Kaneko et al. in 1998 of
a safe and effective technique of local delivery of melphalan
through the opjhthalmic artery.[16] They described the technique
of introducing a microballoon catheter into the cervical segment
of internal carotid artery distal to the ophthalmic artery ostium
through a transfemoral approach. On inflation of the balloon
and occlusion of internal carotid artery, melphalan was injected
into the opthalmic artery. They called this technique “selective
ophthalmic artery infusion” (SOAI). They reported the initial
results of the procedure in 187 patients who underwent
563 SOAIs with 97.5% technical success rate. They had a
technical failure in 14 patients including nonvisualization of
opthalmic artery in five eyes.[16] However, they noted that there
were several small arterial branches arising proximal to the
origin of opthalmic artery through which the drugs could flow
making it not truly “selective.” They also suggested that if the
catheter was to be introduced into the orifice of the opthalmic
artery, drug flow to the other branches could be avoided,
although their technique did not allow it because a guide wire
was not used to advance the catheter at that time. With this, a
new era was set, in treating retinoblastoma with IAC infusion,
targeting the tumor directly through opthalmic artery, avoiding
systemic side effects and improving globe salvage.[12,18‑22]
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terminologies are summarized in Table 1. According to a survey
conducted in 2014, there were 31 centers in 19 countries where
IAC was being performed as primary and secondary treatment
for retinoblastoma, and the results were promising.[31]

Technique
The procedure is performed by a skilled neurointerventional
radiologist or neurosurgeon in unison with the ocular oncologist,
pediatric oncologist, anesthesiologist, pharmacist, and ancillary
staff making this a truly multidisciplinary approach. IAC is
performed as an outpatient procedure under general anesthesia
in a well‑equipped catheterization laboratory/interventional
suite. Intravenous heparin (50 IU/kg body weight) is infused
for anticoagulation achieving a clotting time two to three times
baseline. Topical phenylephrine is routinely applied locally
along the distribution of the supratrochlear artery to minimize
chemotherapy flow onto the forehead. A nasal vasoconstrictor
is also used routinely to minimize chemotherapy flow into the
nose. The femoral artery of the ipsilateral side is accessed under
aseptic precaution with a 4‑French pediatric arterial sheath. This
is carefully guided under fluoroscopy up the aorta, into the carotid
artery, then to the internal carotid artery, and then to the ostium
of opthalmic artery selectively [Fig. 1]. Serial angiograms are

Subsequently, Gobin et al. in 2006 popularized the
refined technique of direct catheterization of the opthalmic
artery with a guide wire that made it truly selective and
they called it super‑selective intraophthalmic artery
chemotherapy.[23] Abramson et al. reported the initial results
that were encouraging.[19] There was no looking back; IAC
soon emerged as one of the first‑line management options in
retinoblastoma.[24] We also witnessed the various applications
of IAC, such as primary and secondary IAC (first‑line and
second‑line therapy after failure of IVC), tandem therapy (in
bilateral retinoblastoma), bridge chemotherapy (sequential with
systemic chemotherapy), minimal exposure (<2 sessions), and
rescue IAC (for recurrence after previous IAC).[25‑30] Pertinent
Table 1: Standard terminologies used in intraarterial
chemotherapy
Terminologies

Methods and indication of IAC
administration

Primary IAC

First line of management

Secondary IAC

Secondary treatment after failure of
previous treatment (IVC, external beam
radiotherapy, plaque brachytherapy)

Tandem IAC

Administered bilaterally simultaneously

Bridge IAC

Initiating the treatment with IVC, especially
in neonates, then followed by IAC
Re-use IAC following IAC for recurrent
tumor or subretinal seeds or vitreous seeds

Rescue IAC

Figure 1: Selective ophthalmic artery chemotherapy is performed by
passing the catheter via ICA through the femoral artery into the OA
ostium. (route marked in blue) Alternate route is catheterization of MMA
via ECA and IMA. (route marked in green). In Japanese technique,
ICA distal to OA ostium is occluded with balloon. (CCA=common
carotid artery; ECA= external carotid artery; ICA=internal carotid
artery; IMA- internal maxillary artery; MMA= middle meningeal artery;
OA= ophthalmic artery; LA= lacrimal artery; SOA= supraorbital artery)
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performed to evaluate the cerebral vasculature and identification
of the vascular branches. Choroidal blush is identified in the
angiogram. After ensuring the placement of the catheter at the
opthalmic artery ostium with an angiogram, chemotherapeutic
drugs diluted in 30 mL of normal saline are infused slowly
and manually over 30 min in a pulsatile fashion to disrupt the
laminar flow and homogeneous distribution of drugs along the
targeted vascular anatomy. Repeat angiogram is performed after
the procedure to exclude a thromboembolic event. In bilateral
cases (tandem IAC), microcatheter is withdrawn upto the aorta
and then redirected to the contralateral internal carotid artery upto
the opthalmic artery ostium and a similar procedure is continued.
Dose adjustment is done to avoid cumulative toxicity in tandem
IAC. The microcatheter and guide wire are slowly removed. Use of
guide wire is no longer preferred in the current technique to reduce
opthalmic artery spasm. Femoral artery hemostasis is attained by
manual compression followed by a compressive bandage. Patients
are discharged the same day after observation for 4–6 hours. Topical
corticosteroids in tapering doses along with short‑acting mydriatics
are prescribed. Oral aspirin in the dose of 1–2 mg/kg body weight
is advised for 2 weeks postoperatively. Currently, this technique
is widely accepted and practiced worldwide. Post procedure, after
7–10 days, a complete blood count is recommended for all patients.
An alternate route is used when the opthalmic artery cannot
be identified due to a small arterial size or vasospasm during the
procedure and difficulty in catheterization due to anatomical
variation in the branching. In 7% of cases, the opthalmic artery
arises from the middle meningeal artery, unlike the rest from
internal carotid artery.[32] In such situations, catheterization is
through the middle meningeal artery, a branch of the internal
maxillary artery of the external carotid artery [Fig. 1].
The Japanese technique of microballoon catheterization and
occlusion is considered as an alternative technique during difficult
catheterization of opthalmic artery. By inflating the balloon just
distal to the opthalmic artery, temporary balloon occlusion of
the internal carotid artery is attained. This enables local delivery
and prevents seepage of chemotherapeutic drugs to the anterior,
middle, and posterior cerebral arteries. In this technique, the
chemotherapeutic drugs are diluted in 6 cc normal saline and
infused rapidly over 4 minutes followed by deflation of the balloon
to prevent untoward cerebral ischemic complications [Fig. 1].[16]
Technical challenges are encountered in the intervention
suite. Most commonly, there can be instability of the catheter
at the face of the opthalmic artery ostium and rarely spasm of
the opthalmic artery. Stenzel et al. recently reported technical
interruption in 42% (29/98) cases due to meningeal collateral,
difficulty in cannulating opthalmic artery, and alternative
blood supply to the retina.[33] Yet another factor identified is
the hemodynamic instability between ICA and external carotid
artery leading to flow reversal (vascular steal) in opthalmic artery
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and inadequate choroidal blush. This may lead to suboptimal
delivery of drugs and reduced response to IAC. To improve the
drug delivery, an alternate route of middle meningeal artery was
suggested by Klufas et al. in this scenario.[34] Bertelli et al. occluded
external carotid artery with cyanoacrylate adhesives to prevent
this instability in hemodynamics in 26 eyes undergoing 73
catheterizations.[35] In their series of 17 eyes, Quinn et al. required
alternate route in five, with eye salvage in 80% (four of five). In
one of the patients, there was no internal carotid artery supply
to orbit; hence frontal branch of the superficial temporal artery
was catheterized. The patient developed forehead necrosis and
complete ptosis that required reconstructive surgery.[36]

Chemotherapeutic Agents and Dosage
Inomato and Kaneko in their initial series used melphalan
as single‑agent chemotherapeutic drug for IAC. In their
study, melphalan was found to be the most potent agent for
retinoblastoma when compared with other tumoricidal agents.[17]
Later, Abramson et al. added carboplatin and topotecan, putting
forward the popular triple‑drug regimen.[19,23] [Table 2]. Side
effects and complications mainly depend on the dosage of
chemotherapeutic agents and should be titrated accordingly.
Daniels et al. found excellent vitreous and retinal drug penetration
of melphalan in IAC in an in vivo study in a rabbit model.[37]
1. Melphalan is an alkylating agent that is a nitrogen mustard
derivative. The effective and safe dose delivered to the
eye is <0.5 mg/kg with minimal systemic absorption and
negligible neutropenia. It is essential to filter melphalan
before injection as the particles can embolize/crystallize the
ocular vessels leading to vision‑threatening complications.
Suzuki et al. injected 1 mg of betamethasone after melphalan
injection to prevent vasculitis. Dose ranges from 3 to 7.5 mg
depending on the age of the patient [Table 2]
2. Topotecan, a semi‑synthetic camptothecin derivative, is a
topoisomerase 1 inhibitor that was popular for periocular
chemotherapy in advanced RB. Periocular topotecan has less
local tissue toxicity compared with periocular carboplatin.
Laurie et al. reported that the effect of topotecan and
carboplatin combination was superior to the vincristine,
etoposide, and carboplatin combination in their animal
study.[38] Dosage recommended is 0.5–2 mg [Table 2]
3. Carboplatin is a platinum‑based derivative with fewer
side effects than its precursor cisplatin. It is one of the
drugs in the time‑tested multiagent IVC protocol that
has proven beneficial in RB. It is also used as a periocular
chemotherapeutic agent. Carboplatin is used in the
triple‑drug protocol for unilateral IAC along with melphalan
and topotecan. In bilateral IAC, to avoid the cumulative
toxicity of melphalan leading to myelosuppression,
dosage of melphalan is reduced with the addition of
carboplatin without compromising the effect of IAC.[24] The
recommended dosage is 15–30 mg [Table 2].

Table 2: Intra‑arterial chemotherapy ‑ drugs and dosage
Drugs

Standard dose in mg

Dose range in mg

Melphalan*

5

3‑7.5

‑ Drug of choice in groups B and C as single agent

Topotecan
Carboplatin

1
20

1‑2
15‑30

‑ Advanced retinoblastoma with diffuse vitreous seeds (groups D and C)
‑ Tandem IAC ‑ to reduce the cumulative toxicity of melphalan, given alternatively
‑ Recurrence after IAC
‑ Suboptimal response to melphalan and topotecan combination

*Melphalan has to be filtered before infusion

Indications

Years of
study

1998‑2007

2006‑2010

2008‑2009

2009‑2013

2008‑2010

2010‑2012

2008‑2010

Authors
(year, country)

Suzuki et al.12
(2011, Japan)

Gobin et al.23
(2011, USA)

Peterson et al.42
(2011, USA)

Munier et al.43
(2011, Switzerland)

Muen et al.45
(2012, UK)

Thampi et al.46
(2013, USA)

Venturi et al.44
(2013, Italy)
39

20

15

13

146
(96)

40
(100)

NA

31
(96.8)

26 (100)

259
(98.5)

1469 (98.8)

NA (1‑9)

2.5 (1‑5)*

2 (1‑3)

3 (1‑3)

1.4 (1‑2)

3 (1‑7)

3 (1‑18)

M

M

M

M

M

M, T,
C

M

Primary (17)
Secondary (24)

Primary (12)
Secondary (8)

Secondary (15)

Primary (9)
Secondary (4)

Secondary (17)

Primary (39)
Secondary (56)

Secondary

Total no. of
No. of
Drugs Indication
catheterizations
sessions
(no.of eyes)
(% success rate) median (range)

41
96

66.5
87.5

80

100
100

76.5

82
58

60*

Eye
salvage
in %

79

70

80

100

76.5

70

60

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

2 (2)

8 (2)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

12 (3)

Eyelid edema, hyperemia
Ptosis
Retinopathy
Strabismus
Lash loss
Frontal alopecia
Choroidal atrophy
Systemic toxicity

Eyelid edema/erythema
Dacryohemorrhea
Vitreous hemorrhage
Cataract
Choroid atrophy
OA spasm
Neutropenia
Bronchospasm

Orbital edema
Forehead hyperemia
Retinal detachment
3rd cranial nerve palsy
RPE loss
Epistaxis
Anaphylactoid reaction

Choroidal vasculopathy
Retinal detachment
Retinal arteriolar emboli
Vitreous hemorrhage

Delayed vitreous hemorrhage

Periocular edema
Hyperemia
Avascular retinopathy
Cataract
Eyelash loss

Periorbital swelling
Severe orbital cellulitis
Diffuse chorioretinal atrophy
Bradycardia
Bronchospasm

Overall eye Metastasis Death Complications
salvage in %
n (%)
n (%)
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Contd...

1‑27

15*

7

7
(mean)

8.6 (mean)

13

74

Median
follow up
in months

June 2019

17

95

408

No. of
eyes

Table 3: Intra‑arterial chemotherapy‑ Worldwide Review Over Two Decades from 1998‑2019
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Years of
study

2009‑2013

2011‑2013

2008‑2012

2009‑2012

2010‑2013

Authors
(year, country)

Shields et al.25
(2014, USA)

Taich et al.47
(2014, Argentina)

Parareda et al.48
(2014, Spain)

Ghassemi et al.49
(2014, Iran)

Ong et al.50
(2015, Taiwan)

Table 3: Contd...

17

24

12

49
(91)

NA

33
(94)

66 (NA)

198
(99.5)

2.8 (1‑6)

1‑2

2.5 (1‑5)

NA

3 (1‑7)

M, T,
C

M

M, T

M, T,
C

Primary (6)
Secondary (11)

Primary (6)
Secondary (18)

Primary (12)

Primary (5)
Secondary (22)

Primary (36)
Secondary (34)

Total no. of
No. of
Drugs Indication
catheterizations
sessions
(no.of eyes)
(% success rate) median (range)

66.5
54.5

84
56

58

100
59

72
62

Eye
salvage
in %

59

62.5

58

77.8

67

3 (17.5)

0 (0)

0 (0)

0 (0)

0 (0)

2 (1)

0 (0)

0 (0)

0 (0)

0 (0)

Lid edema
Retinal artery occlusion
Chorioretinal atrophy
Vitreous hemorrhage
3rd nerve palsy
6th nerve palsy

Eyelid edema
Vitreous hemorrhage
Choroidal ischemia
CRAO
Retinal hemorrhage
Retinal detachment
NVG
Ptosis
Retinal fibrosis
Cyclitic membrane
Phthisis

Diffuse arteriolar sclerosis
RPE hypertrophy
Partial retinal atrophy
OA spasm

3rd cranial N. palsy
Hematological toxicity

Eyelid edema
Blepheroptosis
Forehead hyperemia
Scalp alopecia
BRVO
Partial choroidal vascular
occlusion
Optic neuropathy
Vitreous hemorrhage
Phthisis bulbi
OA spasm
OA occlusion

Overall eye Metastasis Death Complications
salvage in %
n (%)
n (%)

Indian Journal of Ophthalmology
Contd...

22

16.8

29.5

11.7

19

Median
follow up
in months

744

27

70

No. of
eyes
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Years of
study

2011‑2014

2008‑2015

2011‑2015

2008‑2013

NA

2013‑2015

2011‑2013

Authors
(year, country)

Akyuz et al.51
(2015, Turkey)

Abramson et al.24
(2016, USA)

Tuncer et al.52
(2016, Turkey)

Michaels et al.53
(2016, USA)

Leal‑ Leal et al.54
(2016, Mexico)

Reddy MA et al.55
(2017, UK)

Chen et al.56
(2017, China)

Table 3: Contd...

107

9

11

19

343
(98.5)

27
(NA)

NA

87
(100)

76 (97.3)

418
(NA)

NA

3.1
(2‑5)

3 (2‑4)

3
(all eyes)

5 (mean)
(2‑10)

3 (2‑5)

3.4 (mean)
(1‑11)

2.3 (mean)
1‑7

M, T

M, T

M, T

M, T,
C

M, T,
C

M, T,
C, Mtx

M

Primary (30)
Secondary (77)

Secondary

Secondary

NA

Primary (Group D)

Primary (60)
Secondary (60)

Primary (44)
Secondary (12)

Total no. of
No. of
Drugs Indication
catheterizations
sessions
(no.of eyes)
(% success rate) median (range)

93
79

66

55

NA

67

NA
NA

75
64

Eye
salvage
in %

78.5

66

55

58

67

97

66

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

2 (3.5)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (0.8)

2 (3.5)

Eyelid edema
Conjunctival congestion
Retinal hemorrhage
Vitreous hemorrhage
Retinal vasculopathy
OA spasm
Transient myelosupression

Autonomic episode
Ptosis
Temporary 6th nerve palsy
Choroidal ischemia

Stroke
Nausea, vomitting

Localized erythema
Eyelid edema
Eyelash/brow loss
Forehead skin
hyperpigmentation
Conjunctival chemosis
Neutropenia
Bronchospasm
Carboplatin anaphylaxis

Eyelid edema
Ptosis
Forehead hyperemia
Chorioretinal atrophy
Retinal detachment
Vitreous hemorrhage

Neutropenia

Transient eyelid swelling
Conjunctival chemosis
Ptosis
Forehead hyperemia
Ocular motility limitation
Mild proptosis
RPE alteration
Optic atrophy

Overall eye Metastasis Death Complications
salvage in %
n (%)
n (%)
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Contd...

13.6
(mean)

21

57 (mean)

13

29

36

Median
follow up
in months

June 2019

24

120

56

No. of
eyes
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2013‑2016

2010‑2017

2013‑2015

2012‑2015

2009‑2017

Rishi et al.56
(2017, India)

Ammanuel et al.58
(2018, USA)

Hua J et al.59
(2018, China)

Radros et al.60
(2018, Sweden)

Rojanaporn et al.61
(2019, Thailand)
27

11

84

43

10

No. of
eyes

80 (94)

39 (77)

200
(94.5)

125
(100)

38
(NA)

3 (1‑7)

NA

2.8
(mean)

2.8

4 (3‑5)

M, T,
C

M

M, T

M, T,
C

M, T

Primary (7)
Secondary (20)

NA

Secondary

NA

Primary (2)
Secondary (8)

Total no. of
No. of
Drugs Indication
catheterizations
sessions
(no.of eyes)
(% success rate) median (range)

57
50

73

30

NA

100
75

Eye
salvage
in %

52

73

30

35

80

1 (3.7)

0 (0)

0 (0)

0 (0)

0 (0)

1 (3.7)

0 (0)

0 (0)

0 (0)

0 (0)

Cerebrovascular emboli
Renal effects
Groin hematoma
Eyelid/periocular edema
Heterophoria
Exophthalmos
Ptosis
Periorbital erythema
OA spasm
Transient visual impairment
Papilledema
Retinal detachment
TIA
Occlusive vasculopathy
Vitreous hemorrhage
Retinal artery precipitation
Strabismus

Eyelid edema
Vitreous hemorrhage
Retinal vasculopathy
OA spasm
Transient vomiting
Transient myelosupression

Stroke
Systemic toxicity

Forehead pigmentation
OA spasm
BRVO
Cataract
Optic atrophy

Overall eye Metastasis Death Complications
salvage in %
n (%)
n (%)

32 (mean)

NA

14.2 (mean)

31.8

28

Median
follow up
in months

Indian Journal of Ophthalmology

occlusion; NVG= neovascular glaucoma; BRVO= branch retinal vein occlusion; TIA= transient ischemic attack
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*Calculated from the statistics available in the publication. M= melphalan; T= topotecan; C= carboplatin; Mtx= methotrexate; NA=not available; OA= ophthalmic artery; RPE= retinal pigment epithelium; CRAO= central retinal artery

Years of
study

Authors
(year, country)

Table 3: Contd...
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Treatment Protocol
Overall, the dosage of chemotherapeutic drugs for IAC
depends on the patient’s age and severity or extent of the
disease. The largest series from Japan used melphalan as
single agent in 408 eyes.[12] Abramson et al. reported beneficial
effects from triple‑drug regimen (melphalan, topotecan, and
carboplatin).[19,23] Shields et al. primarily prefer melphalan as
single agent with additional topotecan in eyes with the presence
of extensive seeding.[24] Topotecan has the advantage of longer
t1/2 when compared with melphalan.
Till date, there are no standardized protocols or universal
consensus in place regarding drugs and dosage for IAC. In
the systematic review by Yousef et al., melphalan was the most
common single agent of choice. As an accepted standard of care,
IAC is administered every 4 weeks for three sessions.[39] There
are studies that have reported sessions beyond 3, upto 11.[24]
The median number of sessions as reported by Suzuki et al.,
Gobin et al., and Shields et al. was 3.[12,23,25] The aim is to achieve
maximum tumoricidal benefits with reduced local toxicity and
vision‑threatening complications. Sessions are extended in
selective cases for improved response. If complete regression
of the tumor can be achieved with additional transpupillary
thermotherapy and/or cryotherapy post IAC, it is always preferred
over additional IAC weighing the risks and benefits. Shields et al.
showed excellent response to minimal exposure IAC upto two
sessions for group B and C eyes. In rescue IAC, where reinitiation
of IAC is performed in the post‑IAC recurrence, Shields et al.
reported a median of three sessions with typically higher dose
melphalan and addition of topotecan for tumor control.[29] Most
of the centers avoid IAC in neonates and infants <6 months of age.
Chen et al. performed 27 catheterizations in 13 eyes of neonates at
a mean age of 7.9 (range 4.6–10.9) weeks. One patient developed
ICA spasm and the procedure was aborted.[40] Our team reported
successful IAC in a 2‑month‑old neonate.[41]

Indications
1. Primary therapy/first‑line management
‑ Unilateral retinoblastoma: groups B, C, and D (cT1b, cT2, cT3, cT4)
‑ Bilateral retinoblastoma: groups D and E (cT3)
Our team generally prefers to use IAC for unilateral disease
and IVC for bilateral disease. We typically avoid tandem IAC
for bilateral retinoblastoma, especially if the better eye has
visual potential, to avoid unpredictable vascular toxicity of IAC
leading to suboptimal vision affecting the quality of life of the
child. Retinal and choroidal vasculopathy due to ischemia and/
or occlusion can lead to irreversible blindness. In such situation,
it is desirable to initiate systemic IVC as primary management
for tumor control in both eyes along with eye and vision salvage
of the better eye. However, IAC can be considered in the worse
eye as secondary line of management for eye salvage.

extension
3. Extraocular or orbital extension of retinoblastoma
4. Trilateral retinoblastoma
5. Patients with systemic metastasis: hematogenous and
central nervous system
5. Tumors amenable to focal transpupillary thermotherapy,
cryotherapy, and/or intravitreal chemotherapy.
Unlike systemic IVC, IAC does not have systemic chemoprotective
effect, as it is a localized delivery of chemotherapeutic drugs. Risk
of systemic micrometastasis remains in advanced intraocular and
extraocular disease. Metastasis can go undetected clinically in
advanced diseases and poor prognosis for life salvage with IAC.
Yousef et al. in their systematic review reported 2.1% (13/613)
metastatic rate following IAC.[39]

Treatment Outcomes
Various studies have published the outcome of IAC in
terms of eye salvage, recurrence, metastasis, and death.
However, the choice of drugs, dosage, and techniques vary
widely[12,23‑25,42‑61] [Table 3]. Lack of prospective randomized
clinical trials is a challenge in evaluating the efficacy.
Eye salvage
With IAC, group B and C eyes have an excellent outcome,
ranging from 95% to 100% eye salvage, similar to IVC[25]
[Figs. 2 and 3]. The beneficial effect of IAC over IVC was found
to be more pronounced in group D eyes, the majority of the
eyes that otherwise required external beam radiotherapy or
enucleation. Various studies reported improved eye salvage
in the IAC era, especially in advanced intraocular disease
[Table 4].
Shields et al. compared IAC (n = 49) and IVC (n = 42) treated
eyes with unilateral retinoblastoma. Eye salvage rate was
significantly higher (91%) in group D eyes with IAC, compared
with the IVC group (48%).[62] Munier et al. compared group D
eyes treated with IAC versus IVC and showed 100% globe
Table 4: Outcome of IAC according to International
Classification of Intraocular RB
Authors (no.of eyes)

Eye salvage according to groups in %
A

B

C

D

E

Suzuki et al (408)12

100

88

65

45

30

Abramson et al (120)24

100

100

100

100

90

Chen et al (107)

NA

100

100

78.5

62

NA

100

100

94

36

0

90

64

69

50

Ronjanaporn et al (27)61

NA

100

100

75

9

Munier et al (25)63

NA

NA

NA

100

NA

2. Secondary therapy/second‑line management after prior
treatment failure
‑ Recurrent tumor, subretinal seeds or both
‑ Persistent tumor, subretinal seeds or both.

Tuncer et al (24)52

NA

NA

NA

67

NA

Ghassemi et al (24)49

NA

100

0

72

66

Thampi et al (20)46

100

100

100

50

33

Ong et al (17)50

NA

67

100

100

57

Contraindications

Parareda et al (12)48
Leal‑Leal et al (11)54

NA
NA

100
50

100
100

50
30

NA
NA

1. Eyes with neovascular glaucoma, hyphema, vitreous hemorrhage,
aseptic preseptal or orbital cellulitis, and prephthisical
2. Radiological evidence of optic nerve extension and scleral

56

Shields et al (70)25
Ammanuel et al (43)58

*Most ocular oncologists do not treat group A with IAC due to potential
toxicities and they treat with local laser therapy like laser photocoagulation
and cryotherapy
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Figure 2: (a) Fundus photograph of a 10‑month‑old Caucasian
infant showing solitary exophytic macular retinoblastoma with focal
subretinal seeds and subretinal fluid in the right eye (OD), classified as
group C. (b) B‑scan ultrasonography confirming a calcified intraocular
measuring 7.11 mm in thickness. After receiving three sessions of
IAC, (c) the tumor is completely regressed (Type 1) with resolution of
subretinal fluid and (d) the tumor has reduced to 3.71 mm thickness

a

c
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a

b

c

d

Figure 3: (a) Fundus photograph of a 6‑month‑old Caucasian infant
showing solitary endophytic retinoblastoma with diffuse subretinal
and vitroeus seeds in the left eye (OS). (b) B‑scan ultrasonography
confirming a large calcified intraocular mass occupying >50% of
globe and measuring 12.20 mm thickness. After receiving four
sessions of IAC, (c) tumor is regressed (Type 3) with calcified
subretinal and vitreous seeds and (d) the tumor has reduced
to 5.00 mm thickness, with visible partial posterior vitreous
detachment

b
a

b

c

d

d

Figure 4: (a) Fundus photograph of a 7‑month‑old Chinese infant
showing large, exophytic, retinoblastoma in the OS with retinal
detachment, subretinal seeds and no view of optic disc, and
(b) following two sessions of IAC, the tumor is completely regressed
(Type 1) and the optic nerve (arrow) is visible. (c) Fundus photograph
of a 9‑month‑old Indian infant showing large, exophytic, retinoblastoma
in OD with total retinal detachment (arrow), subretinal seeds, and no
view of optic disc, and (d) following three sessions of IAC, the tumor
is regressed (Type 3) and there is complete resolution of subretinal
fluid with visible optic disc

salvage with IAC and 60% with IVC. The relapse rate of IAC was
24% compared with 52% with IVC.[63] The treatment duration
was shorter in IAC for tumor control, 6.7 months in IAC versus
14.2 months in IVC.[63] Abramson et al. reported 78.6% eye
salvage in group D eyes with IAC. They also estimated the 2‑year
probability of 64% eye salvage after IAC in eyes with vitreous
seeds, 83% in eyes with subretinal seeds, and in 80% with both.
Eye salvage in advanced retinoblastoma was significantly better
in treatment‑naïve eyes compared with non‑naïve eyes (80.2%

Figure 5: (a) Fundus photograph of a 2‑year‑old Caucasian infant
showing large, exophytic/endophytic (group D) with vitreous and
subretinal seeds, overlying the optic nerve in OS. (b) B‑scan
ultrasonography confirming a large calcified intraocular mass
measuring 10.74 mm thickness. After receiving four sessions of IAC,
(c) the tumor is regressed (Type 3) and located away from the optic
disc with flat fovea and potential for vision. (d) The tumor has reduced
to 4.81 mm thickness

vs 58.4%). [64] Tuncer et al. reported 66.6% eye salvage in
treatment‑naïve group D eyes [Figs. 4 and 5].
Currently, the combination of two localized treatment
strategies, IAC with intravitreal chemotherapy (IvitC), has
further improved the outcome. [52] Shields et al. showed
significant improvement in the outcome of IAC with
additional administration of IvitC compared with IAC alone.
They noted that there was a difference (IAC vs IAC plus
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IvitC as needed) in the need for enucleation overall (44%
vs 15%, P = 0.01), especially for group E eyes (73% vs 27%,
P = 0.04).[65] Dalvin et al. compared eyes that received IAC
alone with those who required additional IvitC for vitreous
seeds and subretinal seeds. Of the 49 eyes classified as
groups D and E, 20 eyes required additional IvitC where
50% eyes had vitreous seeds in all four quadrants. In these
eyes, enucleation or radiation was eliminated in 75% with
IAC alone and 65% with combined IvitC.[66] Francis et al.
reported similar estimated 1‑year ocular survival with IAC in
the pre‑IvitC era (96%) and IvitC era (96%).[67] In the review
by Yousef et al., overall eye salvage was 66% in 502 eyes, 86%
in groups A–C, and 57% in groups D and E.[39] Primary IAC
had better eye salvage rate than secondary IAC. From the two
largest studies, eye salvage after primary IAC was 72%–86%
and 58%–62% with secondary IAC.[12,25] Peterson et al. achieved
76.5% eye salvage (n = 17) with IAC in eyes with vitreous seeds
that were refractory to prior treatments and were awaiting
enucleation.[42] In 12 eyes, melphalan doses were escalated
upto 7.5 mg for optimal response.[42] According to Gobin et al.,
Kaplan–Meier estimate for eye survival rates at 2 years was
82% and 58% for primary (n = 39) and secondary (n = 56) IAC,
respectively [Fig. 6c and d].[23]
Local tumor recurrence
New tumor formation in eyes treated with systemic IVC has
been reported as 23%–48%.[68‑71] In an early report, Shields
et al. found that IAC alone provided excellent solid tumor
and seed control.[20] Following IAC (mean three sessions),
they demonstrated complete control of solid tumor in 88%,
subretinal seeds in 82%, and vitreous seeds in 67%.[20] Later, use
of IvitC added further control to vitreous seeds.[65] Abramson
et al. analyzed similar cohort of heritable RB patients who
underwent IVC and IAC (primary and secondary) for new
tumor occurrence after treatment and found new tumors
in 2.4% of treatment‑naïve eyes (primary IAC) and 8% in
secondary IAC compared with 47% in the IVC group.[72]

a

b

c

d

Figure 6: (a) Fundus picture showing tumor and vitreous seeds’
recurrence in OD post IAC four sessions in a group D eye (arrow with
dotted lines) of a 2‑year‑old Chinese boy. (b) After rescue IAC two
sessions, tumor and seeds completely regressed. (c) Tumor recurrence
with vitreous clouds after six cycles of systemic chemotherapy in a
3‑year‑old Indian boy in OS. (d) Following three sessions of IAC, tumor
is totally calcified and vitreous is clear
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Francis et al. recently reported the overall estimate of
recurrence‑free survival (RFS) post IAC at 1 year and 2 years
as 76.3% and 70%, respectively.[67] They evaluated 407 eyes, of
which 111 eyes had recurrence. Of these eyes, 54% received
focal laser or cryotherapy, plaque brachytherapy, and IvitC,
and 29% required only focal cryotherapy and laser. Additional
IAC was performed in 30% of eyes with recurrence. It was also
estimated that RFS was 92% at 2 years if the eyes remained
recurrence‑free at the end of 1 year.[67]
The strategy of reusing IAC after initial IAC for both
primary and secondary retinoblastomas was termed as rescue
IAC by Shields et al.[30] Repeat cycles of IAC (recue IAC) were
performed following tumor recurrence in 12 eyes at a mean
of 5 months after the last IAC cycle. Dosage was escalated
upto 7.5 mg of melphalan, and additional topotecan 1 mg
was generally infused leading to eye salvage (rescue IAC) at
67% (n = 8) [Fig. 6a and b].
Systemic metastasis
The primary goal of retinobalstoma management has
always been life salvage. Since IAC is a local therapy but
not systemically chemoprotective, the concern of undetected
systemic micrometastasis in advanced retinoblastoma prevails.
In the largest series of IAC by Suzuki et al., there were 12
deaths, of which 8 were due to metastasis of central nervous
system (CNS) (n = 1) and multiple other sites (n = 5).[12] A recent
multicenter survey including six prominent IAC centers from
the United States (n = 2), Europe (n = 2), Brazil (n = 1), and
Argentina (n = 1) analyzed metastatic deaths.[72] Over a period
of 10 years, 3 of 1139 patients were reported to have metastasis
from one center alone (Argentina).[73] Gobin et al. from the
United States had previously reported 2 of 78 patients who
developed metastasis at a median follow‑up of 13 months.[23]
From Australia, Mathew et al. reported a case of hematogenous
metastasis in a child with group E unilateral retinoblastoma
who received four sessions of IAC, and subsequently required
high dose of systemic chemotherapy and radiation. [74]
Ronjanaporn et al. from Thailand had 1 patient out of 27 (4%)
who died due to CNS metastasis.[61] Akyuz et al. from Turkey
reported two deaths post‑enucleation in a progressive disease
following IAC.[51] Both the patients had histopathological
high‑risk features: choroid and anterior chamber invasion in
one and optic nerve cut end involvement in the other. Three
patients (3/17, 17.5%) had metastasis to CNS as reported by
Ong et al. from Taiwan. It was classified as group E in two
patients and group B in one patient where all eyes were
enucleated for vitreous hemorrhage after IAC. All three
eyes had histopathological high‑risk features with choroid
and optic nerve invasion. Despite adjuvant chemotherapy
post‑enucleation, two patients died.[50] Our team has been
fortunate to have used IAC for nearly 12 years in carefully
selected hundreds of cases of retinoblastoma and we have had
no incidence of metastasis or death.[20,25,27,29,62,65,66]
Kaliki et al. analyzed histopathological features in
519 enucleated eyes and found high‑risk invasive features in
17% of group D eyes and 24% of group E.[75] Taking this into
account, IAC should be avoided in eye with clinical risk factors
for systemic metastasis (neovascular glaucoma, hyphema,
vitreous hemorrhage, preseptal cellulitis, orbital cellulitis,
tumor filing the eyeball, prephthisis, and phthisis bulbi).
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Yousef et al. in their review showed 2.1% of metastatic
disease in 613 patients.[39] There is a strong belief that the risk
of metastasis and death is not worth in these eyes that has
poor prognosis for eye and vision salvage. Rodriguez et al.
attempted high‑dose IAC for extraocular retinoblastoma with
chiasmal invasion using carboplatin combined with intrathecal
topotecan, and after three sessions there was radiological
evidence of partial resolution of the orbital mass and chiasmal
lesion, and the eye was enucleated. Remission was documented
in CNS – cerebrospinal fluid cytology after three sessions of
intrathecal topotecan. Thereafter, the child was lost to follow‑up
and further status was not known on stability or recurrence or
metastasis or death.[76]

aborting the procedure or alternate route for completion of the
procedure. Being a neuroinvasive procedure, IAC carries the
risk of neurological complications. Ronjanaporn et al. reported
transient ischemic attack in one case.[61] Three cases of stroke
following IAC were reported so far.[54,58,80] One case of stroke
presenting as seizures related to cerebral ischemia in the territory
of ipsilateral internal carotid artery after selective ophthalmic
artery IAC was reported. However, the patient made complete
neurological recovery.[58] The other was a child with atrial
septal defect who presented with status epilepticus after 2 days
followed by upper extremity weakness. Magnetic resonance
imaging revealed cerebral infarction in the ipsilateral middle
cerebral artery territory and an incomplete circle of Willis.[80]

Occurrence of secondary primary malignancies (SPMs) is
well established in heritable retinoblastoma group of patients
especially when exposed to radiation. Suzuki et al. reported
SPM in 11 patients out of the 343 patients undergoing IAC at
a mean follow‑up of 6.2 years, all of whom have undergone
radiotherapy and 9 had bilateral retinoblastoma. The estimated
cumulative incidence was 1.3% at 5 years.[12] Habib et al. analyzed
214 patients with heritable and/or bilateral retinoblastoma who
received IAC over a period of 10 years (2006–2016) with a mean
follow‑up of 36 months. Four patients had pinealoblastoma at
an interval of 13–21 months after detection of retinoblastoma
and were estimated to be 2.7% at 5 years that is comparable to
studies pre‑IAC era.[77]

Ocular side effects
The common and self‑resolving complications are
periocular edema and hyperemia (34%), ptosis (13.5%), focal
madarosis (10.5%), and forehead erythema (3%). Application
of sympathomimetic drugs topically over the forehead
can reduce the periorbital signs to some extent [Fig. 7].
Neurological complications included third and sixth cranial
nerve palsy. Muen et al. reported 6 of 17 (40%) cases with third
cranial nerve palsy with ptosis and pupillary involvement.[45]
All except one case resolved within 2–6 months. Shields et al.
reported a case of optic neuropathy, and three cases of optic
atrophy are reported.[25,51,57] The procedure carries the risk
of permanent vision‑threatening complications. Associated
ischemic and occlusive chorioretinopathy, central retinal
artery occlusion, vitreous hemorrhage, and retinal detachment
remain a major concern when vision salvage is one of the
major goals of procedure. Especially in those patients with
remaining one eye having visual potential, be it unilateral or
bilateral IAC [Fig. 8].

Treatment Complications
IAC has proven time and again to be efficacious in tumor
control with potential eye and vision salvage. But it is not
completely devoid of vision‑threatening ocular vascular
events, mostly related to chemotherapeutic drug toxicity.
We have witnessed higher complication rates in the past
when compared with the current scenario probably due
to the learning curve in the technique and the modality
of administration of drugs.[12,78-80] There has been no death
reported due to the procedure itself.
Systemic side effects
The major advantage of IAC was to reduce morbidity related
to systemic toxicity of chemotherapeutic agents. However,
grades 1–4 neutropenia was reported with IAC in few cases.
Overall, 5.9% suffered neutropenia, of which only 0.2% required
blood transfusion. Others were bronchospasm and autonomic
episodes. Ophthalmic artery spasm was reported that lead to

a

Dalvin et al. compared the early era (2009–2011) and current
era (2012–2017) to evaluate the vascular complications and
found a reduction from 59% to 9%.[79] Spasm of ophthalmic
artery was 27% in the early era, whereas 0% in the current era.
Choroidal ischemia had reduced from 14% to 4%.[79] In a case–
control study, Maidana et al. evaluated subfoveal choroidal
thickness with spectral domain optical coherence tomography
in 18 eyes. Thickness was significantly reduced in treated eyes
versus healthy control eyes, with or without clinical evidence
of choroidal atrophy.[81]
The cause of vascular events is still unclear, whether it is
related to technique, cumulative drug toxicity, pH, or drug
distribution, and is often unpredictable. Francis et al. correlated
electroretinogram (ERG) responses with chemotherapeutic

a
b

Figure 7: (a) Forehead hyperemia along the distribution of supraorbital
artery and blepheroptosis in a 6‑month‑old Chinese girl after first
session of IAC in OD. (b) Ipsilateral alopecia in a 2‑year‑old Chinese
boy following IAC in OD

b

Figure 8: (a) Group D unilateral RB in a 2 year‑old Indian boy with total
retinal detachment in OS. (b) After three sessions of IAC, the tumor
and retinal detachment have completely resolved, but ophthalmic artery
occlusion has lead to optic nerve atrophy and diffuse retinal atrophy
with arteriolar narrowing
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Figure 9: SWOT analysis of IAC

drugs (melphalan, topotecan, carboplatin) and found that
cumulative melphalan was associated with modest change in
ERG amplitudes although temporary.[82] Tse et al. evaluated
the histopathological changes in nonhuman primate
model (Maccaca mullatta) after selective ophthalmic artery IAC
with melphalan (5 mg) and carboplatin (30 mg). Ocular and
orbital vasculature showed significant toxic effects.[83] Steinle
et al. found that there was direct effect of the drugs (melphalan
and carboplatin) to the vascular endothelium and monocytes.[84]
Visual outcome
Not many studies have reported the final visual acuity (VA)
post‑IAC. Suzuki et al. evaluated VA with Landolt ring test in
197 eyes of 246 salvaged eyes. In eyes with tumors sparing the
foveola, 51% retained >20/40 and 36% retained 20/20.[12] Of the
nine eyes that underwent IAC, none had visual deterioration
post‑IAC as reported by Reddy et al. Best‑corrected VA
was ≥20/40in 71% (5/7 eyes) pre‑IAC when compared with
77% (7/9) post‑IAC. All eyes recorded normal ERG post‑IAC
except one who had subtle reduction in rod and cone b‑waves.
The cumulative melphalan dose was the highest (20 mg) in
this cohort.[55] Recently, Levin et al. assessed the pretreatment
ERG with posttreatment VA in 157 group D and E eyes.
Lower pretreatment ERG was associated with higher visual
impairment posttreatment.[85] Munier et al. assessed the final VA
in 12 group D eyes, of which 7 eyes had extramacular tumors;
42% (n = 3) maintained ≥20/40.[63]

Conclusion
IAC has emerged as a promising option for eye salvage,
particularly in advanced intraocular retinoblastoma as primary
and secondary line of management. This modality has gained
tremendous popularity in the developed world. A major
concern in the low‑ and middle‑income countries is the financial
constraint due to high treatment cost. Safer techniques and
optimal dosage of chemotherapeutic agents can minimize

treatment‑associated complications. Despite the expertise,
vascular complications are unpredictable and can still occur in
the most experienced hands. Vision salvage has a crucial role
in a certain set of patients with retinoblastoma. Therefore, risks
and benefits have to be thoroughly assessed, and treatment
strategy has to be chosen accordingly. Collaboration of IAC
treatment centers and merging as one single platform to
standardize drugs, dosage, and technique may further improve
the outcome. Lack of systemic chemoprotective effect of IAC
poses a major threat in certain clinically advanced disease with
high risk of systemic micrometastasis. We have elaborated
this in our strengths/weaknesses/opportunities/threats
(SWOT) analysis of IAC [Fig. 9]. With a decade of experience,
the long‑term prognosis of IAC is yet to be established.
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